Evaluation for clinical utilization of anti-inflammatory agents in spinal cord ischemia.

我们研究了抗肿瘤坏死因子- α药物英夫利昔单抗是否能减轻家兔的缺血性脊髓损伤。我们将家兔分为三组（n=5，除高剂量英夫利昔单抗组外）；对照组、低剂量英夫利昔单抗组（5mg/kg）、高剂量英夫利昔单抗组（10mg/kg）。阻断腹主动脉15分钟，造成脊髓缺血。再灌注后，每天评估后肢运动功能（评分范围：4分，正常至0分，截瘫），连续7天，然后计数前脊髓正常神经元数量。神经学评分组间无显著差异。另一方面，低剂量英夫利昔单抗组正常神经元数量明显多于对照组。提示低剂量英夫利昔单抗（5mg/kg）可保护缺血性脊髓损伤，但临床应用英夫利昔单抗治疗脊髓缺血应谨慎。

We investigated whether the ischemic spinal cord injury in rabbits was reduced by infliximab, an anti- tumor necrosis factor-alpha agent. We assigned rabbits to three groups (n=5, expect high dose infliximab group); a control group, low dose infliximab group (5mg/kg), high dose infliximab group (10mg/kg). Spinal cord ischemia was produced by occluding the abdominal aorta for 15 min. After the reperfusion, hindlimb motor function (score range: 4, normal to 0, paraplegia) was assessed daily for 7 days, and then the number of normal neurons in the anterior spinal cord was counted. There were no significant intergroup differences in neurological scores. On the other hand, the numbers of normal neurons of low dose infliximab group had significantly more than a control group. This results indicate that low dose infliximab(5mg/kg) may protect ischemic spinal cord injury, but clinical utilization of infliximab for spinal cord ischemia should be discreet.